Data on risk-adjusted returns on UK start-ups relative to other countries.

Background

The analysis team is responsible for two datasets on life sciences activity in the UK and how it compares with other countries. One of its publications, the Bioscience and health technology sector statistics, is an official statistic and captures a detailed breakdown of where life sciences activity occurs in the UK, as well as key economic indicators such as employment and turnover. The analysis team is also responsible for publishing the Life sciences competitiveness indicators, a publication which tracks UK performance against international comparators. These two publications form the bulk of the evidence base that supports OLS policy making and key facts and figures for stakeholders. One of the ambitions of the team is to expand the range of data collected on activity in the sector to encompass a broader range of economic indicators, including Gross Value Added, R&D spending, Wages, and workforce statistics, among others.

In addition to this critical evidence base, OLS is also interested in key research questions and evidence to support the development of policy for the Life Sciences Missions, a set of disease and intervention areas identified in the Life Sciences Vision as key areas of intervention to help the NHS to solve some of the biggest healthcare problems of our generation. These range from establishing a strong evidence base on incidence and its regional distribution to identifying potential innovative technologies that could address them. Additionally, the analysis team is also very interested in deepening our understanding of the economic impact and possibilities of the broad area of genomics, as well as understanding the economic impacts and societal benefits that accrue from conducting clinical trials and other forms of R&D in the life sciences.

On the regulatory front, OLS would like to expand its understanding of the main regulatory barriers to the approval and roll-out of new, innovative technologies, as well as understanding the costs and benefits associated with these regulations. We have a limited evidence base for some products but would like to expand that understanding to be better able to assess the impact of specific regulatory interventions. We would also like to have more comprehensive data on the introduction and adoption of these technologies across the country and through the NHS.

On the investment front, we are particularly interested in building a more comprehensive evidence base on the determinants of investment in both manufacturing and R&D facilities, and how elements of both the commercial and business environment affects company location and investment decisions.

Finally, we are very interested in developing a more comprehensive understanding of the manufacturing landscape in the UK, from being able to interrogate the pipeline of new products and innovations in development, to establishing the UK’s manufacturing capabilities for health and supply chain resilience, as well as understanding key challenges faced by companies in terms of access to skilled workers and finance across the country.

Next steps

If you are keen to register your interest in working and connecting with DSIT Digital Technology and Telecoms Group and/or submitting evidence, then please complete the DSIT-ARI Evidence survey - https://dsit.qualtrics.com/jfe/form/SV_cDfmK2OukVAnirs.
Please view full details: https://www.gov.uk/government/publications/department-for-science-innovation-and-technology-areas-of-research-interest/dsit-areas-of-research-interest-2024

Related UKRI funded projects


  • Launchpad Cluster Management - Northern Ireland

    The Northern Ireland (NI) Health and Life Sciences (HLS) sector presents an emerging cluster combining expertise, infrastructure, academia and industry across a DBT designated area of High Potential Opportunity: in Preci...

    Funded by: Innovate UK

    Lead research organisation: HEALTH INNOVATION RESEARCH ALLIANCE

    Why might this be relevant?

    Partially relevant as it focuses on the UK life sciences sector but does not specifically address risk-adjusted returns.

  • BioExchange Australia-UK

    Based in the West Midlands, BIOX i(www.bioexchange.asia) isa challenge-led open innovation and business matching platform, to assist UK life science and medical technology companies to capture key international market op...

    Funded by: Innovate UK

    Lead research organisation: BRITISH CHINA TECHNOLOGY INCUBATOR LTD

    Why might this be relevant?

    Partially relevant as it focuses on UK life science companies engaging with international markets, but does not specifically address risk-adjusted returns.

  • Innovating Medical Technologies across the Yorkshire Region

    The aim of this place based impact acceleration account (PBIAA) is to support the translation of University research in medical technologies into new clinical products and services. There is a vibrant Medical Technolog...

    Funded by: EPSRC

    Lead research organisation: University of Leeds

    Why might this be relevant?

    Partially relevant as it focuses on supporting the translation of University research in medical technologies in the UK, but does not specifically address risk-adjusted returns.

  • West Midlands HealthTech/MedTech ‘6D’ Innovation Accelerator

    The Healthcare Technology and Medical Technology sectors are currently worth £17billion per annum to the UK, and with the ageing population and poor health following the pandemic, are projected to grow to £21...

    Funded by: Innovate UK

    Lead research organisation: UNIVERSITY OF BIRMINGHAM

    Why might this be relevant?

    Partially relevant as it focuses on accelerating new technologies in the healthcare sector, but does not specifically address risk-adjusted returns on UK start-ups.

  • West Yorkshire HealthTech Cluster leadership

    Health Innovation Yorkshire and Humber (formerly the Academic Health Science Network) will work in partnership with West Yorkshire Combined Authority (WYCA) and in support of all the relevant Health Tech and Life Science...

    Funded by: Innovate UK

    Lead research organisation: YORKSHIRE AND HUMBER PARTNERS ACADEMIC HEALTH SCIENCE NETWORK LIMITED

  • Accelerate // Science Creates 2.0

    The ScienceCreates Engineering Biology Accelerator is a unique 9-week hybrid-learning programme which supports the training, growth and success of 24 early-stage founders in Engineering Biology, in partnership with the U...

    Funded by: Innovate UK

    Lead research organisation: SCIENCE CREATES SERVICES LTD

  • Better measurement of the complementarity between UK public, charity and private medical research

    Getting benefits from medical research in terms of preventing or treating illness, advancing scientific knowledge and generating economic wealth often, though not always, involves private industry. The private sector bui...

    Funded by: MRC

    Lead research organisation: King's College London

    Why might this be relevant?

    Partially relevant as it focuses on measuring complementarity between public, charity, and private medical research, but does not specifically address risk-adjusted returns on UK start-ups.

  • British Regen Industry Tool Set (BRITS)

    The British Regen Industry Tool Set (BRITS) is an industry driven project aimed at establishing reliable market data and creating both detailed bioprocess economics models and higher level business models for integration...

    Funded by: Innovate UK

    Lead research organisation: LONZA BIOLOGICS PLC

    Why might this be relevant?

    Not relevant as it focuses on establishing market data and business models for the cell therapy industry, not related to risk-adjusted returns on UK start-ups.

  • Experomental Medicine Network of Excellence

    The UK Science base is recognised as internationally excellent and the translation of this excellence into improvements in clinical practice is essential to ensure the continued delivery of UK economic and health benefit...

    Funded by: Innovate UK

    Lead research organisation: UNIVERSITY OF BIRMINGHAM

  • Industrial Biotechnology Innovation Cluster

    Industrial Biotechnology (IB) is a set of cross-disciplinary technologies that uses biological resources for producing and processing everyday products such as food, fuels, and medicines. The field is poised for dramatic...

    Funded by: EPSRC

    Lead research organisation: University of Manchester

    Why might this be relevant?

    Partially relevant as it focuses on Industrial Biotechnology in the UK, but does not specifically address risk-adjusted returns on start-ups.

Similar ARIs from other organisations